Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL | T.CRDL.W.A

Healthcare
Cardiol Therapeutics Inc. (Cardiol) is a Canada-based clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive... see more

Recent & Breaking News (TSX:CRDL)

Cardiol Therapeutics (TSX:CRDL) expands phase II/III trial of CardiolRx

John Ballem  October 18, 2021

Cardiol Therapeutics Expands LANCER, a Phase II/III Trial of CardiolRx(TM), into Brazil, Mexico, and Canada

Newsfile October 18, 2021

Cardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Newsfile September 16, 2021

Cardiol Therapeutics Announces Acceleration of Expiry Date of Warrants Issued on June 4, 2020

Newsfile September 10, 2021

Cardiol Therapeutics (TSX:CRDL) welcomes Michael J. Willner to the board

John Ballem  September 7, 2021

Cardiol Therapeutics Appoints Michael J. Willner to Its Board of Directors

Newsfile September 7, 2021

Cardiol Therapeutics (TSX:CRDL) receives FDA clearance for phase 2 trial of CardiolRx™

Julia Kennedy  August 24, 2021

Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

Newsfile August 24, 2021

Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL"

Newsfile August 9, 2021

Cardiol Therapeutics (TSX:CRDL) appoints Dr. Guillermo Torre-Amione as Chairman of the Board

Brieanna McCutcheon  July 7, 2021

Cardiol Therapeutics' Board of Directors Appoints Dr. Guillermo Torre-Amione as Chairman

Newsfile July 7, 2021

Cardiol Therapeutics Reports Results of 2021 Annual General and Special Meeting

Newsfile June 30, 2021

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting on June 29th at 4:30 p.m. EDT

Newsfile June 28, 2021

IIROC Trade Resumption - CRDL.WT.A

Canada NewsWire May 12, 2021

Cardiol Therapeutics (TSX:CRDL) closes $22 Million bought deal offering

John Ballem  May 12, 2021

Cardiol Therapeutics Closes $22 Million Bought Deal Offering

Newsfile May 12, 2021

IIROC Trading Halt - CRDL.WT.A

Canada NewsWire May 12, 2021

Cardiol Therapeutics Inc. (TSX:CRDL) upsizes bought deal public offering

John Ballem  May 6, 2021

Cardiol Announces Upsize to Previously Announced Bought Deal Public Offering

GlobeNewswire May 6, 2021

IIROC Trade Resumption - CRDL

Canada NewsWire May 6, 2021